S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Datatec Limited stock logo
DTTLY
Datatec
$3.60
$4.10
$3.22
$4.61
$413.14M0.25418 shsN/A
IQE plc stock logo
IQEPF
IQE
$0.39
-2.5%
$0.28
$0.16
$0.40
$316.30M2.516,042 shs25,025 shs
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
$1.48
+5.7%
$1.48
$0.50
$1.79
$523.27M0.5116,436 shs2,000 shs
Allkem Limited stock logo
OROCF
Allkem
$6.80
+1.5%
$6.80
$5.34
$11.66
N/A1.6814,560 shs1,900 shs
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$29.29
$34.79
$26.85
$46.26
N/A0.2407 shs24 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Datatec Limited stock logo
DTTLY
Datatec
0.00%-7.22%-9.77%-16.67%-21.91%
IQE plc stock logo
IQEPF
IQE
-2.70%+44.16%+34.77%+31.13%+50.90%
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
0.00%0.00%0.00%0.00%0.00%
Allkem Limited stock logo
OROCF
Allkem
0.00%0.00%0.00%0.00%-12.60%
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
-8.33%-8.33%-11.61%-37.97%-40.85%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Datatec Limited stock logo
DTTLY
Datatec
N/AN/AN/AN/AN/AN/AN/AN/A
IQE plc stock logo
IQEPF
IQE
N/AN/AN/AN/AN/AN/AN/AN/A
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
N/AN/AN/AN/AN/AN/AN/AN/A
Allkem Limited stock logo
OROCF
Allkem
N/AN/AN/AN/AN/AN/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Datatec Limited stock logo
DTTLY
Datatec
N/AN/AN/AN/A
IQE plc stock logo
IQEPF
IQE
3.00
BuyN/AN/A
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
N/AN/AN/AN/A
Allkem Limited stock logo
OROCF
Allkem
2.00
HoldN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Datatec Limited stock logo
DTTLY
Datatec
$5.14B0.08$0.77 per share4.70$4.73 per share0.76
IQE plc stock logo
IQEPF
IQE
$207.17M1.53$0.03 per share12.91$0.27 per share1.46
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
$188.53M2.78N/AN/A$4.14 per share0.36
Allkem Limited stock logo
OROCF
Allkem
$1.21BN/A$1.10 per share6.16$8.96 per shareN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$171.15MN/A$3.23 per share9.06$13.04 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Datatec Limited stock logo
DTTLY
Datatec
$80.33MN/A0.006.55N/AN/AN/AN/AN/A
IQE plc stock logo
IQEPF
IQE
-$92.20MN/A0.00N/AN/AN/AN/AN/A
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
-$111.79MN/A0.0013.45N/AN/AN/AN/AN/A
Allkem Limited stock logo
OROCF
Allkem
$441.71MN/A0.0042.50N/AN/AN/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$1.23MN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Datatec Limited stock logo
DTTLY
Datatec
$0.154.17%N/AN/AN/A
IQE plc stock logo
IQEPF
IQE
N/AN/AN/AN/AN/A
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
N/AN/AN/AN/AN/A
Allkem Limited stock logo
OROCF
Allkem
N/AN/AN/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Datatec Limited stock logo
DTTLY
Datatec
0.08
1.05
0.91
IQE plc stock logo
IQEPF
IQE
N/AN/AN/A
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
N/AN/AN/A
Allkem Limited stock logo
OROCF
Allkem
0.08
2.52
2.23
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.13
3.01
2.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Datatec Limited stock logo
DTTLY
Datatec
N/A
IQE plc stock logo
IQEPF
IQE
N/A
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
N/A
Allkem Limited stock logo
OROCF
Allkem
N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/A

Insider Ownership

CompanyInsider Ownership
Datatec Limited stock logo
DTTLY
Datatec
N/A
IQE plc stock logo
IQEPF
IQE
N/A
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
N/A
Allkem Limited stock logo
OROCF
Allkem
N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
1.88%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Datatec Limited stock logo
DTTLY
Datatec
11,009114.76 millionN/ANot Optionable
IQE plc stock logo
IQEPF
IQE
685804.84 millionN/ANot Optionable
OPHIR ENERGY PL/ADR stock logo
OPHRY
OPHIR ENERGY PL/ADR
386353.56 millionN/ANot Optionable
Allkem Limited stock logo
OROCF
Allkem
1,350N/AN/ANot Optionable
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
509N/AN/ANot Optionable

OPHRY, PHMMF, IQEPF, DTTLY, and OROCF Headlines

SourceHeadline
A Path to the CMP Designation: Pharma Forum in TampaA Path to the CMP Designation: Pharma Forum in Tampa
meetingsnet.com - March 20 at 4:59 PM
Pharming Group’s Strong Performance and Growth Prospects Justify Buy RatingPharming Group’s Strong Performance and Growth Prospects Justify Buy Rating
markets.businessinsider.com - March 18 at 1:46 PM
Mar-a-lagoMar-a-lago
newsweek.com - March 16 at 10:00 AM
Pharmas ad theme at this year’s Oscar saw a big shift from 2023Pharma's ad theme at this year’s Oscar saw a big shift from 2023
fiercepharma.com - March 13 at 10:21 AM
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back painPersica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
markets.businessinsider.com - March 7 at 7:03 AM
PharmaKure partners with Sheffield Hallam University to develop epigenetic markers for Alzheimer’s disease predictionPharmaKure partners with Sheffield Hallam University to develop epigenetic markers for Alzheimer’s disease prediction
news-medical.net - March 4 at 4:04 AM
Pharma Mar SAU (PHMR)Pharma Mar SAU (PHMR)
investing.com - February 17 at 3:04 AM
Pharma Forum 2024: Special Elements On and Off SitePharma Forum 2024: Special Elements On and Off Site
meetingsnet.com - February 14 at 6:15 PM
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma MarketPfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market
investorplace.com - February 1 at 2:03 PM
Two new databases combine computer science and pharmaceutical researchTwo new databases combine computer science and pharmaceutical research
msn.com - January 9 at 1:32 PM
First West Africa Healthcare, Lab, & Pharma Week 2024 To Hold In NigeriaFirst West Africa Healthcare, Lab, & Pharma Week 2024 To Hold In Nigeria
msn.com - November 29 at 11:26 PM
Pharma Mar SA PHMPharma Mar SA PHM
morningstar.com - November 6 at 12:33 AM
Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024
markets.businessinsider.com - October 28 at 9:31 AM
A framework for screening pharmaceuticals and personal care products in landfill leachatesA framework for screening pharmaceuticals and personal care products in landfill leachates
phys.org - October 26 at 7:32 PM
Sort Through Highly Undervalued Pharma Stocks to Find the Best Pharmaceutical Stocks, 2023Sort Through Highly Undervalued Pharma Stocks to Find the Best Pharmaceutical Stocks, 2023
industryleadersmagazine.com - September 23 at 12:07 AM
Targeted Education at Pharma Forum EMEA and U.S.Targeted Education at Pharma Forum EMEA and U.S.
meetingsnet.com - September 20 at 7:08 PM
China’s Hengrui Pharma Licenses New Asthma Drug to US’ One Bio for Up to USD1 BillionChina’s Hengrui Pharma Licenses New Asthma Drug to US’ One Bio for Up to USD1 Billion
yicaiglobal.com - August 15 at 9:35 AM
Pharma Mar S.A.Pharma Mar S.A.
barrons.com - July 15 at 3:26 PM
Yifan PharmaceuticalYifan Pharmaceutical
forbes.com - June 21 at 8:33 PM
FTC expands PBM probe, orders records from Emisar PharmaFTC expands PBM probe, orders records from Emisar Pharma
modernhealthcare.com - June 8 at 10:34 PM
PHM.MC - Pharma Mar, S.A.PHM.MC - Pharma Mar, S.A.
finance.yahoo.com - June 6 at 7:41 PM
Austrian study shows transparency of pharmaceutical sponsorship for patient initiatives increased significantlyAustrian study shows transparency of pharmaceutical sponsorship for patient initiatives increased significantly
medicalxpress.com - May 22 at 3:37 PM
‘Phar­ma Bro’ Mar­tin Shkre­lis com­pa­nies file for bank­rupt­cy‘Phar­ma Bro’ Mar­tin Shkre­li's com­pa­nies file for bank­rupt­cy
endpts.com - May 10 at 6:01 PM
NEEDHAM & COMPANY INC. Maintains Pharma Mar (XMAD:PHM) Buy RecommendationNEEDHAM & COMPANY INC. Maintains Pharma Mar (XMAD:PHM) Buy Recommendation
msn.com - April 22 at 8:50 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Datatec logo

Datatec

OTCMKTS:DTTLY
Datatec Limited, together with its subsidiaries, provides information and communication technology (ICT) solutions and services worldwide. It operates in four segments: Westcon International, Logicalis International, Logicalis Latin America, and Corporate and Management Consulting. The company distributes cyber security, network infrastructure, unified collaboration products, data centre solutions, and channel services; and offers financing/leasing solutions for ICT customers. It offers solutions through a network of service providers, systems integrators, and specialty resellers under the Westcon and Comstor brands. The company also provides digital services; and strategic, trusted advisory, modeling, and market intelligence services to the telecoms, media, and technology industries. Datatec Limited was founded in 1986 and is headquartered in Sandown, South Africa.
IQE logo

IQE

OTCMKTS:IQEPF
IQE plc, together with its subsidiaries, develops, manufactures, and sells advanced semiconductor materials. It operates through three segments: Wireless, Photonics, and CMOS++. The company manufactures and sells compound semiconductor materials for the wireless market which includes radio frequency devices for wireless communications, and photonics market, that includes applications that transmit and sense visible and infrared lights, as well as advanced semiconductor materials related to silicon. It operates in the United States, rest of the Americas, France, Germany, Israel, the United Kingdom, rest of Europe, the Middle East, Africa, the People's Republic of China, Japan, Taiwan, and rest of the Asia-Pacific. The company was founded in 1988 and is headquartered in Cardiff, the United Kingdom.
OPHIR ENERGY PL/ADR logo

OPHIR ENERGY PL/ADR

OTCMKTS:OPHRY
Ophir Energy plc engages in the exploration, development, and production of upstream oil and gas properties in Asia and Africa. The company develops offshore and deep-water oil and gas exploration assets. It has 1 billion barrel of oil equivalent of reserves and resources. Ophir Energy plc was founded in 2004 and is headquartered in London, the United Kingdom.
Allkem logo

Allkem

OTCMKTS:OROCF
Allkem Limited engages in the production and sale of lithium and boron in Argentina. Its flagship project is the Olaroz Lithium Facility located in Jujuy province in northern Argentina. Allkem Limited was incorporated in 2005 and is headquartered in Brisbane, Australia.
Pharma Mar logo

Pharma Mar

OTCMKTS:PHMMF
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.